Abstract
Deguelin is the major active ingredient and principal component in cube resin, derived from Lonchocarpus utilis and used as a botanical insecticide and pesticide in Africa, South America and China. A growing body of evidence indicates that deguelin has a very strong anti-tumor effect on malignant cells without compromising normal cells. As a complex natural extract, deguelin interacts with various molecular targets to exert its anti-tumor properties at nanomolar levels. This current review delineates the molecular mechanism of the anti-tumor activities of deguelin in malignancies. Our research shows that the multiple and extensive biological effects of deguelin are mediated via interactions with target points involved in cell proliferation pathways (cyclin D1, pRb), cell apoptosis pathways (NF-κB, IκBα, Bcl-2, Bcl-xl, survivin), the nucleophosmin and nucleoporins pathways (Nup88, Nup98, Nup214), as well as through the regulation of steroid receptor co-activator SRC-3 and DNA Topoisomerase. In addition, deguelin holds a promising efficacy for reversing drug resistance.
Keywords: Anti-tumor, Bcl-xl, Bcl-2, Cyclin D1, Deguelin, IκBα, NF-κB, NPM, NUPs, pRb, SRC-3, Survivin
Current Pharmaceutical Analysis
Title: Molecular Mechanism of Deguelin in Anti-tumor Effect
Volume: 8 Issue: 1
Author(s): Lu Wen and Yan Chen
Affiliation:
Keywords: Anti-tumor, Bcl-xl, Bcl-2, Cyclin D1, Deguelin, IκBα, NF-κB, NPM, NUPs, pRb, SRC-3, Survivin
Abstract: Deguelin is the major active ingredient and principal component in cube resin, derived from Lonchocarpus utilis and used as a botanical insecticide and pesticide in Africa, South America and China. A growing body of evidence indicates that deguelin has a very strong anti-tumor effect on malignant cells without compromising normal cells. As a complex natural extract, deguelin interacts with various molecular targets to exert its anti-tumor properties at nanomolar levels. This current review delineates the molecular mechanism of the anti-tumor activities of deguelin in malignancies. Our research shows that the multiple and extensive biological effects of deguelin are mediated via interactions with target points involved in cell proliferation pathways (cyclin D1, pRb), cell apoptosis pathways (NF-κB, IκBα, Bcl-2, Bcl-xl, survivin), the nucleophosmin and nucleoporins pathways (Nup88, Nup98, Nup214), as well as through the regulation of steroid receptor co-activator SRC-3 and DNA Topoisomerase. In addition, deguelin holds a promising efficacy for reversing drug resistance.
Export Options
About this article
Cite this article as:
Wen Lu and Chen Yan, Molecular Mechanism of Deguelin in Anti-tumor Effect, Current Pharmaceutical Analysis 2012; 8 (1) . https://dx.doi.org/10.2174/157341212798995467
DOI https://dx.doi.org/10.2174/157341212798995467 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy New Therapeutic Approaches by Using Microorganism-Derived Compounds
Current Medicinal Chemistry Comparison of Anticancer Properties of Annona muricata L. Acetonic and Methanolic Leaf Extracts
The Natural Products Journal Alpha-Helical Cationic Anticancer Peptides: A Promising Candidate for Novel Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Synthesis and Biological Evaluations of Granulatamide B and its Structural Analogues
Current Medicinal Chemistry A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation
Current Cancer Drug Targets The Role of Long Noncoding RNAs in Progression of Leukemia: Based on Chromosomal Location
MicroRNA Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia
MicroRNA Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Current Cancer Therapy Reviews Polysaccharide-K (PSK) in Cancer - Old Story, New Possibilities?
Current Medicinal Chemistry